semaglutide and the brain VT750 distribution in mouse brain. (A) Acute (B) GLP-1 and the Degenerating Brain:
Description
Women in menopause are turning to GLP1 weight-loss drugs
High demand has created a market for compounded versions of the drug best known as Ozemic or Wegovy, but doctors and the FDA say those versions come with risks.
In the public market, regulators that approve semaglutide as a biosimilar may experience slower uptake as automatic substitution rules are usually restrictive
The following article by Houston Methodist The Woodlands Hospital highlights weight-loss surgery patient Carlos Hernandez who shares his story
This new ice cream set is out of this world.
Explore pharmacokinetic and anti-drug antibody (ADA) assessment strategies for GLP-1 receptor agonists in this expert-led whitepaper from Aragen.
